Globus Medical director sells 30K shares at $74

A Globus Medical director exercised fully vested options for 30,000 shares and sold all 30,000 shares in market transactions on September 15, 2026.

Rhea-AI Filing Summary

GLOBUS MEDICAL INC (GMED) director James R. Tobin reported exercising options and selling shares on September 15, 2026. He exercised options for 15,000 shares at an exercise price of $53.75 and 15,000 shares at $63.68, receiving 30,000 Class A Common shares, then sold 30,000 shares at a weighted average price of $74.5834 in multiple transactions at prices ranging from $74.33 to $74.96. The options exercised were fully vested grants from January 26, 2024 and January 27, 2022, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Exercise and Sale: 30,000 shares ($476K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider TOBIN JAMES R

Role Director

Sold 30,000 shs ($2.24M)

Approx. gross sale proceeds $2.24M

Approx. exercise cost $1.76M

Approx. pre-tax spread $476K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy Class A Common Stock) F2	15,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy Class A Common Stock) F3	15,000	$0.00	$0.00
Exercise	Class A Common Stock	15,000	$53.75	$806K
Exercise	Class A Common Stock	15,000	$63.68	$955K
Sale	Class A Common Stock F1	30,000	$74.5834	$2.24M

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 0 contracts (Direct); Class A Common Stock — 0 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
2. F2. These options were granted on January 26, 2024 and are fully vested.
3. F3. These options were granted on January 27, 2022 and are fully vested.

Key Figures

Shares sold: 30,000 shares Weighted average sale price: $74.5834 per share Sale price range: $74.33–$74.96 per share +3 more

6 metrics

Shares sold 30,000 shares Class A Common Stock sold on September 15, 2026

Weighted average sale price $74.5834 per share Sales of 30,000 shares on September 15, 2026, in multiple trades

Sale price range $74.33–$74.96 per share Price range for the reported sales on September 15, 2026

Options exercised (2024 grant) 15,000 shares at $53.75 per share Fully vested options granted January 26, 2024, exercised September 15, 2026

Options exercised (2022 grant) 15,000 shares at $63.68 per share Fully vested options granted January 27, 2022, exercised September 15, 2026

Total shares from option exercises 30,000 shares Shares of Class A Common Stock received from option exercises on September 15, 2026

Key Terms

weighted average price, fully vested, Class A Common Stock, stock option

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested financial

"These options were granted on January 26, 2024 and are fully vested."

Class A Common Stock financial

"Stock Option (Right to Buy Class A Common Stock)"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

stock option financial

"Stock Option (Right to Buy Class A Common Stock)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GMED director James R. Tobin report on this Form 4?

He reported exercising options for 30,000 shares of Class A Common Stock and selling 30,000 shares on September 15, 2026, in open-market transactions at a weighted average price of $74.5834 per share.

How many Globus Medical (GMED) shares did James R. Tobin sell and at what prices?

He sold 30,000 shares of Class A Common Stock at a weighted average price of $74.5834 per share, in multiple transactions with prices ranging from $74.33 to $74.96, inclusive.

What options did James R. Tobin exercise in the GMED Form 4 filing?

He exercised options for 15,000 shares with an exercise price of $53.75 per share from a grant dated January 26, 2024, and options for 15,000 shares with an exercise price of $63.68 per share from a grant dated January 27, 2022.

Were the options exercised by the GMED director fully vested?

Yes. The filing states that the options granted on January 26, 2024 and January 27, 2022 were fully vested at the time of exercise on September 15, 2026.

Was James R. Tobin’s GMED stock sale under a Rule 10b5-1 trading plan?

No. The filing does not indicate that these transactions were made under a Rule 10b5-1 trading plan; the plan-related checkbox is not marked as affirming such a plan.

What is James R. Tobin’s role at Globus Medical (GMED)?

James R. Tobin is identified in the filing as a director of Globus Medical, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:36 PM Accepted by SEC EDGAR 09/16/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TOBIN JAMES R

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PENNSYLVANIA 19403

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/15/2026		M		15,000	A	$53.75	15,000	D
Class A Common Stock	09/15/2026		M		15,000	A	$63.68	30,000	D
Class A Common Stock	09/15/2026		S		30,000	D	$74.5834(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$53.75	09/15/2026		M			15,000	(2)	01/26/2034	Class A Common Stock	15,000	$0	0	D
Stock Option (Right to Buy Class A Common Stock)	$63.68	09/15/2026		M			15,000	(3)	01/27/2032	Class A Common Stock	15,000	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

2. These options were granted on January 26, 2024 and are fully vested.

3. These options were granted on January 27, 2022 and are fully vested.

	/s/ Kelly G. Huller, Attorney-in-Fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)